Overview

Study of APD421 as PONV Treatment (no Prior Prophylaxis)

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV prophylaxis.
Phase:
Phase 3
Details
Lead Sponsor:
Acacia Pharma Ltd